Hamdi Kobra, Vaezi Maryam, Dagigazar Behrooz, Mehrzad Sadagiani Mahzad, Farzadi Laya, Pashaei-Asl Maryam
Women's Reproductive Health Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.
Adv Pharm Bull. 2012;2(2):233-7. doi: 10.5681/apb.2012.035. Epub 2012 Aug 15.
This study was performed to investigate the incidence of thrombophilic gene mutations in repeated assisted reproductive technology (ART) failures.
The prevalence of mutated genes in the patients with a history of three or more previous ART failures was compared with the patients with a history of successful pregnancy following ARTs. The study group included 70 patients, 34 with three or more previously failed ARTs (A) and control group consisted of 36 patients with successful pregnancy following ARTs (B). All patients were tested for the presence of mutated thrombophilic genes including factor V Leiden (FVL), Methylenetetrahydrofolate reductase (MTHFR) and Prothrombin (G20210A) using real-time polymerase chain reaction (RT- PCR).
Mutation of FVL gene was detected in 5.9% women of group A (2 of 34) compared with 2.8% women (1 of 36) of control group (P = 0.6). Mutation of MTHFR gene was found in 35.3% (12 cases) as compared with 50% (18 cases) of control (35.3% versus 50%; P = 0.23). Regarding Prothrombin, only control group had 5.6% mutation (P = 0.49). No significant differences were detected in the incidences of FVL, Prothrombin and MTHFR in the study group A compared with the control group B.
The obtained results suggest that thrombophilia does not have a significant effect in ART failures.
本研究旨在调查反复辅助生殖技术（ART）失败患者中血栓形成倾向基因突变的发生率。
将有三次或更多次既往ART失败史的患者中突变基因的患病率与ART后成功妊娠的患者进行比较。研究组包括70例患者，其中34例有三次或更多次既往ART失败史（A组），对照组由36例ART后成功妊娠的患者组成（B组）。使用实时聚合酶链反应（RT-PCR）对所有患者进行血栓形成倾向基因突变检测，包括因子V莱顿（FVL）、亚甲基四氢叶酸还原酶（MTHFR）和凝血酶原（G20210A）。
A组5.9%（34例中的2例）女性检测到FVL基因突变，而对照组为2.8%（36例中的1例）女性（P = 0.6）。MTHFR基因突变在A组中为35.3%（12例），而对照组为50%（18例）（35.3%对50%；P = 0.23）。关于凝血酶原，只有对照组有5.6%的突变（P = 0.49）。A组与B组相比，FVL、凝血酶原和MTHFR的发生率无显著差异。
所得结果表明，血栓形成倾向对ART失败没有显著影响。
